Table 5.
Odds Ratios (ORs) and 95% Confidence Intervals (CIs) for the association between Dietary Inflammatory Index (DII) and breast cancer by Hormone Receptors Status.
| Hormone receptor status | N | Quartiles of DII | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Q1 | Q2 | Q3 | Q4 | p-trend | ||||||
| < − 1.67 | ≥ —1.67 < 0.20 | ≥ 0.20 < 1.86 | ≥ 1.86 | |||||||
| OR | 95% CI | OR | 95% CI | OR | 95% CI | OR | 95% CI | |||
| HR-positive* | 687 | 1.00 | Reference | 1.02 | 0.75, 1.38 | 1.27 | 0.95, 1.70 | 1.34 | 1.00, 1.80 | 0.03 |
| HER2-positive‡ | 94 | 1.00 | Reference | 1.82 | 0.88, 3.76 | 2.20 | 1.08, 4.49 | 2.18 | 1.07, 4.41 | 0.03 |
| TN† | 73 | 1.00 | Reference | 1.17 | 0.56, 2.43 | 1.21 | 0.59, 2.47 | 0.94 | 0.45, 1.96 | 0.92 |
The CECILE study, France, 2005–2007.
*HR-positive: Hormone receptor positive tumors, i.e. (ER-positive or PR-positive) and HER2-negative.
‡HER2-positive regardless of the ER or PR status.
†TN triple negative (ER-negative and PR-negative and HER2-negative).
p-trend determined from the model using the median value in each quartile as a continuous variable.
Odds ratios adjusted for study area, age at reference date, history of benign breast, family history of breast cancer in first-degree relatives, age at menarche, parity, age at first full-term pregnancy, breast feeding, menopausal status, current use of hormone therapy, oral contraceptive use and body mass index.